These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31539712)

  • 1. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.
    Rood JJM; van Haren MJ; Beijnen JH; Sparidans RW
    J Pharm Biomed Anal; 2020 Jan; 177():112871. PubMed ID: 31539712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
    Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
    Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study.
    Narayanan S; Yuile A; Venkatesh B; McKay M; Itchins M; Pavlakis N; Wheeler H; Gray L; Wei J; Miller S; Kirwin B; Molloy MP; Clarke S
    Br J Clin Pharmacol; 2024 Aug; 90(8):1942-1951. PubMed ID: 38706157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
    Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
    J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
    Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous determination of icotinib, osimertinib, aumolertinib, and anlotinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
    Xu Y; Qie H; Zhao H; Gao X; Gao J; Feng Z; Bai J; Wang M
    J Pharm Biomed Anal; 2024 Dec; 251():116445. PubMed ID: 39214029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
    Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
    Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.
    Rood JJM; Dormans PJA; van Haren MJ; Schellens JHM; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jul; 1090():14-21. PubMed ID: 29778873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute Bioavailability of Osimertinib in Healthy Adults.
    Vishwanathan K; So K; Thomas K; Bramley A; English S; Collier J
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):198-207. PubMed ID: 29683562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma.
    Zheng X; Wang W; Zhang Y; Ma Y; Zhao H; Hu P; Jiang J
    Biomed Chromatogr; 2018 Dec; 32(12):e4365. PubMed ID: 30119142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
    Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
    J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
    Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
    BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC-MS/MS in Human Plasma: Application in NSCLC Patients.
    Liu Y; Lin Z; Luo W; Pei X; She Z; Sha Z; Guan Y; Ming D; Liang J
    J Chromatogr Sci; 2024 Apr; 62(4):339-346. PubMed ID: 37070405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
    Ahn MJ; Tsai CM; Shepherd FA; Bazhenova L; Sequist LV; Hida T; Yang JCH; Ramalingam SS; Mitsudomi T; Jänne PA; Mann H; Cantarini M; Goss G
    Cancer; 2019 Mar; 125(6):892-901. PubMed ID: 30512189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
    Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
    Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.